CEP 37250
Alternative Names: ART 104; CEP-37250; KHK 2804; SC 104Latest Information Update: 16 Jul 2019
At a glance
- Originator Scancell
- Developer Kyowa Hakko Kirin; Teva Pharmaceutical Industries
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Glycoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 27 Oct 2011 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy) in USA (Parenteral)
- 09 Mar 2011 Preclinical development is ongoing
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon